Analyst lifts Eli Lilly price target on obesity drug momentum
An analyst raised their price target for Eli Lilly, citing continued growth prospects from its obesity medications Mounjaro and Zepbound.
SOURCE: CNBC ↗
What This Means
CNBC has lifted its price target on Eli Lilly, citing continued momentum in the obesity-drug market where the company competes with Novo Nordisk. Obesity drugs drive recurring revenue and expand addressable markets for pharmaceutical companies, supporting higher valuations as adoption widens and pricing holds.
Sources (1)
Every claim below links directly to the original reporting it was drawn from. Penblock synthesizes and cross-references these sources — it doesn't originate the reporting.
- CNBCOct 29, 2026Read the original report at CNBC ↗
How This Could Play Out
First assessed Oct 29
Resolved
POSSIBLEEli Lilly shares rise as obesity-drug adoption reaches saturation and pricing stabilizes at premium levels, validating the higher valuation.
Status quo
LIKELYEli Lilly trades sideways as obesity-drug sales grow in line with analyst expectations, leaving the price target as a neutral anchor rather than a catalyst.
Worsens
POSSIBLEEli Lilly shares fall as competitive pressure from Novo Nordisk or new entrants erodes pricing power and margins in obesity drugs, forcing downward revisions.
SPONSORED
More on GLP-1 Drug Market
- Eli Lilly raises full-year guidance as Zepbound, Mounjaro sales accelerateOct 29
- Cramer: Tech insiders recommend biotech stock over AI playsOct 26
- Novo Nordisk's oral obesity drug proves effective for patients transitioning from injectionsSep 30
Get the market digest by email
One email each morning: yesterday's key story and what it means for markets. Free.